TY - JOUR
T1 - Neurotrophic effects of the peptide NAP
T2 - A novel neuroprotective drug candidate
AU - Gozes, Illana
AU - Spivak-Pohis, Irit
PY - 2006
Y1 - 2006
N2 - This short review outlines the scientific progression from the neuropeptide vasoactive intestinal peptide as a neuroprotective agent that acts through glial cells to increase and modulate the synthesis and secretion of novel neuroprotective substances. Recent development in the studies on activity-dependent neuroprotective protein (ADNP) and activitydependent neurotrophic factor (ADNF) and short peptide derivatives of these proteins, ADNF-9 and NAP suggest that these peptides are neurotrophic and promote neurite outgrowth. These short peptides hold promise in future neuroprotective/ neurotrophic drug development. Clinical development of NAP is currently in progress by Allon Therapeutics, Inc.
AB - This short review outlines the scientific progression from the neuropeptide vasoactive intestinal peptide as a neuroprotective agent that acts through glial cells to increase and modulate the synthesis and secretion of novel neuroprotective substances. Recent development in the studies on activity-dependent neuroprotective protein (ADNP) and activitydependent neurotrophic factor (ADNF) and short peptide derivatives of these proteins, ADNF-9 and NAP suggest that these peptides are neurotrophic and promote neurite outgrowth. These short peptides hold promise in future neuroprotective/ neurotrophic drug development. Clinical development of NAP is currently in progress by Allon Therapeutics, Inc.
UR - http://www.scopus.com/inward/record.url?scp=33745685544&partnerID=8YFLogxK
U2 - 10.2174/156720506777632790
DO - 10.2174/156720506777632790
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.shortsurvey???
AN - SCOPUS:33745685544
SN - 1567-2050
VL - 3
SP - 197
EP - 199
JO - Current Alzheimer Research
JF - Current Alzheimer Research
IS - 3
ER -